Companies
Qlucore Expands Into Bladder Cancer Diagnostics With Lund University Partnership
The company expects that this work to develop and validate classifier models for bladder cancer will lead to a CE mark for its Qlucore Diagnostics software platform.
The firm's next move will be to pit aumolertinib against AstraZeneca's Tagrisso, the new standard of care in EGFR-mutated NSCLC.
Prostate Cancer UK Funds Study of Angle's Parsortix Liquid Biopsy Test in Prostate Cancer
The trial at Barts Cancer Institute will follow 200 prostate cancer patients over five years and gauge if the CTC test can identify who will recur after surgery.
Bayer Cancels Cell Therapy Licensing Deal With Atara Biotherapeutics
Bayer has notified Atara of plans to terminate its exclusive worldwide licensing deal for the mesothelin-directed cell therapies ATA3271 and ATA2271.
While low FGFR biomarker testing rates may be contributing to the drug's slow adoption, the analysis found low uptake even among patients who did get tested.